Your browser is no longer supported. Please, upgrade your browser.
Settings
MRK Merck & Co., Inc. daily Stock Chart
MRK [NYSE]
Merck & Co., Inc.
IndexDJIA S&P500 P/E25.79 EPS (ttm)3.31 Insider Own0.10% Shs Outstand2.58B Perf Week1.97%
Market Cap220.09B Forward P/E16.08 EPS next Y5.31 Insider Trans-29.78% Shs Float2.57B Perf Month8.22%
Income8.76B PEG2.70 EPS next Q1.15 Inst Own78.00% Short Float0.69% Perf Quarter4.00%
Sales43.07B P/S5.11 EPS this Y33.70% Inst Trans-0.69% Short Ratio1.74 Perf Half Y13.47%
Book/sh10.65 P/B8.02 EPS next Y11.89% ROA10.00% Target Price88.93 Perf Year39.96%
Cash/sh3.41 P/C25.02 EPS next 5Y9.54% ROE28.20% 52W Range59.80 - 84.67 Perf YTD11.71%
Dividend2.20 P/FCF72.35 EPS past 5Y10.60% ROI11.70% 52W High0.81% Beta0.58
Dividend %2.58% Quick Ratio1.10 Sales past 5Y-0.80% Gross Margin69.10% 52W Low42.74% ATR1.25
Employees69000 Current Ratio1.40 Sales Q/Q7.80% Oper. Margin24.40% RSI (14)76.57 Volatility1.48% 1.46%
OptionableYes Debt/Eq0.94 EPS Q/Q321.80% Profit Margin19.50% Rel Volume0.92 Prev Close84.49
ShortableYes LT Debt/Eq0.83 EarningsJul 30 BMO Payout64.50% Avg Volume10.20M Price85.36
Recom1.80 SMA204.69% SMA507.61% SMA20011.66% Volume9,354,658 Change1.03%
May-28-19Initiated Goldman Neutral
May-13-19Upgrade Atlantic Equities Neutral → Overweight
Oct-16-18Reiterated Citigroup Buy $70 → $79
Oct-09-18Resumed Guggenheim Buy
Apr-23-18Upgrade Goldman Neutral → Buy
Apr-17-18Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18Upgrade Barclays Equal Weight → Overweight $62 → $64
Mar-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Feb-14-18Reiterated Leerink Partners Mkt Perform $67 → $66
Feb-07-18Reiterated Morgan Stanley Equal-Weight $60 → $63
Jan-16-18Upgrade SunTrust Hold → Buy
Nov-28-17Resumed BofA/Merrill Buy $64
Nov-24-17Reiterated Deutsche Bank Hold $62 → $59
Oct-31-17Upgrade Jefferies Underperform → Hold
Oct-30-17Downgrade SunTrust Buy → Hold
Oct-30-17Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-30-17Downgrade Barclays Overweight → Equal Weight $72 → $62
Oct-18-17Upgrade Citigroup Neutral → Buy
Aug-09-17Upgrade HSBC Securities Reduce → Hold
Jul-31-17Reiterated UBS Buy $70 → $72
Jun-19-19 11:34AM  Pfizer Stock Is The Biggest Pharma But Should You Buy It? Investor's Business Daily
10:21AM  Merck's Keytruda Gets 2nd Label Expansion Approval in June Zacks
07:51AM  The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut Benzinga
06:45AM  AstraZeneca and Mercks LYNPARZA® (olaparib) Approved in Japan as First-Line Maintenance Therapy in Patients with BRCA-Mutated Advanced Ovarian Cancer Business Wire
Jun-18-19 05:45PM  Merck (MRK) Outpaces Stock Market Gains: What You Should Know Zacks
10:04AM  Merck KGaA -- Moody's: Versum shareholders approve acquisition by Merck KGaA Moody's
09:18AM  Novo Nordisk's Victoza Gets FDA Nod for Pediatric Patients Zacks
08:59AM  AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use Zacks
07:09AM  Shares of cancer-therapy companies skyrocket after Pfizer acquisition news MarketWatch
06:45AM  FDA Approves Mercks KEYTRUDA® (pembrolizumab) as Monotherapy for Patients with Metastatic Small Cell Lung Cancer (SCLC) with Disease Progression on or After Platinum-Based Chemotherapy and at Least One Other Prior Line of Therapy Business Wire
06:30AM  LYNPARZA® (olaparib) Approved in the EU for Use as First-Line Maintenance Therapy in Patients With BRCA-Mutated Advanced Ovarian Cancer Business Wire
03:02AM  UPDATE 1-AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment Reuters
02:35AM  AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment Reuters
Jun-17-19 06:13PM  Bayer to Invest 5 Billion Euros in Weedkiller Research Zacks
05:26PM  J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study Zacks
03:41PM  Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz Zacks
03:09PM  New Targets for Merck Stock as Charts Point Higher TheStreet.com
02:58PM  The 5 Worst Dow Jones Stocks So Far in 2019 InvestorPlace
07:02AM  How Many Merck & Co., Inc. (NYSE:MRK) Shares Have Insiders Sold, In The Last Year? Simply Wall St.
Jun-15-19 12:38PM  The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs Benzinga
Jun-14-19 05:21PM  Agilent Announces Receipt of FDA Approval for pharmDX Assay Zacks
03:14PM  U.S. drugmakers file lawsuit against rule requiring drug prices in TV ads Reuters
01:43PM  WHO panel decides not to declare Ebola emergency - statement Reuters
12:06PM  3 Big Pharma Stocks to Buy Right Now Zacks
10:07AM  Merck Plans Its First Investor Day in 5 Years. Heres What to Watch. Barrons.com
09:12AM  Dow 30 Stock Roundup: United Technologies-Raytheon Merger, Merck's Tilos Buyout Zacks
08:42AM  Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod Zacks
Jun-13-19 04:12PM  Amgen, Biogen, Gilead and Novo Nordisk have very high capacity for M&A, says Moodys MarketWatch
10:26AM  Alkermes Initiates Monothearpy Expansion Phase of ALKS 4230 Zacks
09:31AM  Keytruda & 4 Other Reasons to Invest in Merck's (MRK) Stock Zacks
08:37AM  IBM, Walmart, Merck in blockchain collaboration with FDA Reuters
08:05AM  IBM, KPMG, Merck and Walmart to collaborate as part of FDA's program to evaluate the use of blockchain to protect pharmaceutical product integrity PR Newswire
Jun-12-19 06:21PM  Novartis Reports Data on Cosentyx for Psoriatic Arthritis Zacks
08:33AM  Merck's Keytruda Wins FDA Nod for First-Line Head/Neck Cancer Zacks
08:31AM  Ebola outbreak in Congo causes first death in Uganda Financial Times
08:28AM  Boost Your Portfolio's Health With These 3 Big Drug Stocks Zacks
06:00AM  This Merck subsidiary is expanding in Albany and hiring American City Business Journals
Jun-11-19 02:50PM  Stoke Therapeutics boosts IPO goal by 40 percent American City Business Journals
09:14AM  FDA Greenlights Merck's Blockbuster Drug Keytruda For First-Line Treatment Of Head, Neck Cancer Benzinga
09:03AM  Lilly Announces Tradjenta Cardiovascular Outcome Study Data Zacks
08:53AM  Merck (MRK) to Buy Private Biotech Tilos for Up to $773M Zacks
07:12AM  UPDATE 1-Merck's Keytruda wins FDA approval to treat head and neck cancer Reuters
06:45AM  FDA Approves Two New Indications for Mercks KEYTRUDA® (pembrolizumab) Business Wire
Jun-10-19 05:45PM  Merck (MRK) Gains But Lags Market: What You Should Know Zacks
04:28PM  Dow logs 6-day winning streak as U.S.-Mexico trade tensions recede MarketWatch
01:19PM  Merck Strikes $773M Deal For Privately Held Tilos Therapeutics Benzinga
11:34AM  Mercks Baby Biotech Splurge Wont Fix Its Reliance on Keytruda Bloomberg
11:04AM  Merck snaps up preclinical Lexington biotech for up to $773M American City Business Journals
10:27AM  Merck to buy Tilos Therapeutics in deal valued at up to $773 million American City Business Journals
09:57AM  The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca Zacks
09:48AM  The Zacks Analyst Blog Highlights: Microsoft, Cisco, Merck and Chevron Zacks
07:02AM  Merck to buy cancer-treatment biotech Tilos Therapeutics for up to $773 million MarketWatch
06:45AM  Merck to Acquire Tilos Therapeutics Business Wire
05:39AM  Stocks - Dow Jumps Triple Digits as Trump Touts Tariff Success; M&A Supports Investing.com
Jun-08-19 04:09PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts Benzinga
Jun-07-19 11:04AM  AstraZeneca's Calquence Meets Endpoint in 2nd CLL Study Zacks
10:21AM  Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache Zacks
08:41AM  How Does Marka S.A. (WSE:MRK) Affect Your Portfolio Volatility? Simply Wall St.
07:52AM  Dow 30 Stock Roundup: UNH to Hike Dividend, MRK Zerbaxa's New Indication Gets FDA Nod Zacks
07:30AM  5 Top Dow Stock Gainers of Past Month Still Holding Momentum Zacks
06:47AM  Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar? Zacks
05:00AM  9 interesting things heard during BIO 2019 (Photos) American City Business Journals
Jun-06-19 04:40PM  Is Merck & Co., Inc. (MRK) A Good Stock To Buy ? Insider Monkey
09:09AM  Was ASCO Quieter for Big Drug/Biotech Stocks This Year? Zacks
08:15AM  Better Buy: GlaxoSmithKline vs. Merck Motley Fool
Jun-05-19 03:11PM  Cancer-Fighting Stocks & ETF: What You Need to Know Zacks
09:15AM  Why Merck (MRK) is a Great Dividend Stock Right Now Zacks
07:10AM  Investors Arent Likely to Clean up on Procter & Gamble Stock InvestorPlace
Jun-04-19 05:30PM  Seattle Genetics, Astellas' Cancer Candidate Attains 44% ORR Zacks
10:32AM  Aduro Stock Crashes After ASCO Updates on Cancer Candidate Zacks
10:18AM  Merck's Antibiotic Zerbaxa Gets FDA Nod for New Indication Zacks
09:30AM  Company News For Jun 4, 2019 Zacks
09:03AM  Bristol-Myers (BMY) Presents Multiple Data on Opdivo at ASCO Zacks
02:57AM  Nikkei flat as trade woes, strong yen saps risk appetite; SoftBank Group falls Reuters
Jun-03-19 05:45PM  Merck (MRK) Gains As Market Dips: What You Should Know Zacks
05:04PM  US STOCKS-Nasdaq confirms correction as Facebook, Alphabet, Amazon drag Reuters
04:55PM  FDA Approves Mercks ZERBAXA® (ceftolozane and tazobactam) 3g Dose for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Business Wire
04:15PM  LYNPARZA® (olaparib) Phase 3 SOLO3 Trial Demonstrated a 72% Objective Response Rate in Patients with Platinum-Sensitive Relapsed Germline BRCA-mutated Advanced Ovarian Cancer Compared to 51% of Patients Receiving Chemotherapy Business Wire
03:59PM  Merck wins U.S. FDA approval for expanded use of antibiotic Reuters
03:35PM  Merck wins U.S. FDA approval for expanded use of antibiotic Reuters
03:25PM  US STOCKS-Wall Street falls as Facebook, Alphabet, Amazon drag Reuters
02:46PM  Why Cancer-Fighting Stocks & ETFs Are Soaring Zacks
02:16PM  Merck Presents Updated Results for Investigational Therapy Tepotinib Demonstrating Durable Clinical Response in Patients with Advanced NSCLC with METex14 Skipping Mutations PR Newswire
11:52AM  Novartis (NVS) Announces Various Data Presentations at ASCO Zacks
11:17AM  US STOCKS-Wall St edges higher, boosted by healthcare; Alphabet, Amazon pressure Nasdaq Reuters
10:42AM  AstraZeneca's Imfinzi Shows Long-Term Benefits in Lung Cancer Zacks
10:25AM  US STOCKS-Wall St dips as regulatory fears hit Alphabet, Amazon Reuters
10:25AM  Merck KGaA, Darmstadt, Germany Presents Updated Results for Investigational Therapy Tepotinib Demonstrating Durable Clinical Response in Patients with Advanced NSCLC with METex14 Skipping Mutations PR Newswire
09:42AM  Roche Presents Positive Data on Xolair & Updates From ASCO Zacks
09:39AM  Merck's Keytruda Improves 5-Year Survival in Lung Cancer Zacks
Jun-02-19 01:10PM  Lynparza stalls pancreatic cancer in patients with BRCA mutations -study Reuters
12:09PM  Lynparza stalls pancreatic cancer in patients with BRCA mutations -study Reuters
07:30AM  LYNPARZA® (olaparib) First-Line Maintenance Therapy Nearly Doubled the Time Without Disease Progression or Death in Phase 3 POLO Trial for Patients with Germline BRCA-Mutated Metastatic Pancreatic Cancer Business Wire
Jun-01-19 07:30AM  Merck's Keytruda sets new 5-year survival standard for advanced lung cancer Reuters
07:30AM  Five-Year Survival Data for Mercks KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer (NSCLC) from First KEYNOTE Trial at 2019 ASCO Annual Meeting Business Wire
May-31-19 03:59PM  Veeva Stock Will Help You Ignore the Trade War Tensions InvestorPlace
02:04PM  Jefferson unveils $7 million Institute for Bioprocessing (Photos) American City Business Journals
01:13PM  Merck & Co., Inc. (NYSE:MRK) Has Attractive Fundamentals Simply Wall St.
08:29AM  Drug and Healthcare Stocks to Keep Your Portfolio Healthy InvestorPlace
08:11AM  Roche (RHHBY) Up 6.3% YTD on Strong Demand for New Drugs Zacks
Merck & Co., Inc. provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases. It also provides neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, thyroid, and cervical cancer, as well as brain tumors; and prevent diseases caused by human papillomavirus, as well as offers vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it provides antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, bovine, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments; diabetes mellitus treatment and anthelmintic products; products to treat fleas and ticks in dogs and cats; fertility management products for horses; vaccines for dogs, cats, and horses; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Intec Pharma Ltd. The company serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, distributors, veterinarians, animal producers, and managed health care providers. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Karachun Rita ASr. VP Fince-Global ControllerMay 10Option Exercise0.003,292022,412May 13 05:06 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 10Option Exercise0.004,389071,993May 13 05:05 PM
Fleming MichaelSVP Chief Ethics & Com OfficerMay 10Option Exercise0.001,50903,317May 13 05:05 PM
Nally MichaelEVP, Chief Marketing OfficerMay 10Option Exercise0.001,81104,376May 13 05:06 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 07Option Exercise39.2925,000982,25092,604May 09 06:11 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 07Sale77.7325,0001,943,18367,604May 09 06:11 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 04Option Exercise0.001,212019,717May 07 08:32 PM
Fleming MichaelSVP Chief Ethics & Com OfficerMay 04Option Exercise0.0069202,046May 07 08:32 PM
Zachary JenniferEVP, General CounselMay 04Option Exercise0.005,77205,772May 07 07:42 PM
Nally MichaelEVP, Chief Marketing OfficerMay 04Option Exercise0.001,29802,935May 07 07:40 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 04Option Exercise0.001,904068,542May 07 07:37 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthMay 03Option Exercise39.2935,0001,375,150106,064May 07 08:33 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthMay 03Sale80.0035,0002,800,00071,064May 07 08:33 PM
Merck & Co., Inc.10% OwnerApr 08Buy16.004,121,68365,946,92812,955,016Apr 09 06:27 PM
Davis Robert MEVP, Global Svcs & CFOMar 25Option Exercise58.22192,57211,211,542330,232Mar 27 05:45 PM
Davis Robert MEVP, Global Svcs & CFOMar 25Sale82.38192,57215,863,119137,660Mar 27 05:45 PM
FRAZIER KENNETH CChairman, President & CEOMar 20Option Exercise39.29192,7367,572,597990,451Mar 20 06:49 PM
FRAZIER KENNETH CChairman, President & CEOMar 20Sale82.05192,73615,813,372797,715Mar 20 06:49 PM
FRAZIER KENNETH CChairman, President & CEOMar 13Option Exercise39.2918,725735,705816,440Mar 14 06:38 PM
FRAZIER KENNETH CChairman, President & CEOMar 13Sale82.0018,7251,535,454797,715Mar 14 06:38 PM
FRAZIER KENNETH CChairman, President & CEOMar 05Option Exercise39.296,961273,498804,676Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 05Sale82.006,961570,809797,715Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 04Option Exercise39.2913,144516,428810,859Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 04Sale82.0113,1441,077,875797,715Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOFeb 22Option Exercise39.2953,9612,120,128745,911Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 22Sale80.0253,9614,318,089691,950Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 21Option Exercise39.2941,9921,649,866733,942Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 21Sale80.0041,9923,359,452691,950Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 19Option Exercise39.2942,7001,677,683734,650Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 19Sale80.0242,7003,416,944691,950Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 15Option Exercise39.2992,9133,650,552784,863Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 15Sale80.0392,9137,436,162691,950Feb 19 05:35 PM
Karachun Rita ASr. VP Fince-Global ControllerFeb 14Option Exercise59.1664,6623,825,55180,837Feb 14 06:02 PM
Karachun Rita ASr. VP Fince-Global ControllerFeb 14Sale78.9664,6625,105,95116,175Feb 14 06:02 PM
WEEKS WENDELL PDirectorFeb 13Option Exercise24.305,000121,5005,100Feb 14 06:02 PM
WEEKS WENDELL PDirectorFeb 13Sale78.715,000393,548100Feb 14 06:02 PM
Chattopadhyay SanatExe V-P & Pres. MMDFeb 12Option Exercise38.1873,7272,815,241125,194Feb 14 06:02 PM
Chattopadhyay SanatExe V-P & Pres. MMDFeb 12Sale78.6273,7275,796,30651,467Feb 14 06:02 PM
BRUN LESLIE ADirectorFeb 08Option Exercise24.305,000121,5005,000Feb 11 05:33 PM
BRUN LESLIE ADirectorFeb 08Sale77.223,052235,6811,948Feb 11 05:33 PM
FRAZIER KENNETH CChairman, President & CEOFeb 05Option Exercise39.29231,5669,098,228923,516Feb 06 05:30 PM
FRAZIER KENNETH CChairman, President & CEOFeb 05Sale78.08231,56618,079,654691,950Feb 06 05:30 PM
PERLMUTTER ROGER MExe V-P & Pres, MRLNov 08Option Exercise44.98225,44310,140,426366,998Nov 08 04:31 PM
PERLMUTTER ROGER MExe V-P & Pres, MRLNov 08Sale75.27225,44316,967,967141,555Nov 08 04:31 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Option Exercise54.6836,2181,980,40082,481Nov 08 04:31 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Sale75.1436,2182,721,34846,263Nov 08 04:31 PM
Schechter Adam HEVP & Pres-Global Human HealthNov 01Option Exercise39.29277,87910,917,866277,879Nov 02 04:44 PM
Schechter Adam HEVP & Pres-Global Human HealthNov 01Sale73.81277,87920,510,9450Nov 02 04:44 PM
Watson AshleySVP Chief Ethics & Com OfficerOct 31Option Exercise58.3647,0362,745,21756,806Nov 01 05:07 PM
Watson AshleySVP Chief Ethics & Com OfficerOct 31Sale74.3347,0363,496,1589,770Nov 01 05:07 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthOct 30Option Exercise34.1925,467870,71782,135Nov 01 05:07 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthOct 30Sale72.0025,4671,833,73956,668Nov 01 05:07 PM
FRAZIER KENNETH CChairman, President & CEOOct 02Option Exercise36.56279,85010,231,316971,800Oct 03 05:26 PM
FRAZIER KENNETH CChairman, President & CEOOct 02Sale72.07279,85020,168,258691,950Oct 03 05:26 PM
Merck & Co., Inc.10% OwnerOct 01Buy15.00666,6669,999,9902,723,509Oct 02 02:31 PM
FRAZIER KENNETH CChairman, President & CEOSep 18Option Exercise36.56279,85110,231,353971,801Sep 19 05:43 PM
FRAZIER KENNETH CChairman, President & CEOSep 18Sale70.08279,85119,611,818691,950Sep 19 05:43 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Option Exercise36.56100,0003,656,000100,000Sep 18 04:49 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Sale70.187,360516,51155,406Sep 18 04:49 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Sale70.18100,0007,017,7800Sep 18 04:49 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 03Option Exercise34.8629,2081,018,17680,675Aug 06 04:49 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 03Sale65.2029,2081,904,36251,467Aug 06 04:49 PM
Karachun Rita ASr. VP Fince-Global ControllerAug 02Sale65.015,000325,04016,175Aug 02 05:07 PM
FRAZIER KENNETH CChairman, President & CEOJul 31Option Exercise33.49228,0917,638,768938,788Aug 01 05:12 PM
FRAZIER KENNETH CChairman, President & CEOJul 31Sale65.00228,09114,826,691710,697Aug 01 05:12 PM